Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Shares Outstanding (Weighted Average) (2020 - 2025)

Oncology Institute's Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $92.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 23.11% year-over-year to $92.4 million; the TTM value through Dec 2025 reached $92.4 million, up 23.11%, while the annual FY2025 figure was $92.4 million, 23.11% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $92.4 million in Q4 2025 per TOI's latest filing, up from $89.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $93.2 million in Q2 2025 to a low of $62.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $74.8 million, with a median of $73.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 1088.96% in 2021, then increased 0.27% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $66.2 million in 2021, then rose by 9.91% to $72.8 million in 2022, then grew by 1.31% to $73.7 million in 2023, then grew by 1.76% to $75.0 million in 2024, then rose by 23.11% to $92.4 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Shares Outstanding (Weighted Average) are $92.4 million (Q4 2025), $89.3 million (Q3 2025), and $93.2 million (Q2 2025).